The Course of Cognitive Impairment in Preclinical Alzheimer Disease

Abstract
IDENTIFYING INDIVIDUALS who are at increased risk of developing Alzheimer disease (AD) is currently a topic of great theoretical interest and practical importance.1,2 As more effective pharmacological therapies become available, the administration of these agents to individuals who are subtly impaired may render the treatments more effective.3